Application of microphysiological systems for nonclinical evaluation of cell therapies

Autor: Candarlioglu PL; 3D and 3Rs Ltd., Cambridge, UK; previously at Complex In Vitro Models, GSK, Stevenage, UK., Delsing L; Cell & Gene Therapy Safety, Clinical Pharmacology & Safety Science, R&D, AstraZeneca, Mölndal, Sweden., Gauthier L; Drug Safety Research and Evaluation, Takeda Pharmaceuticals, Cambridge, MA, USA., Lewis L; Nonclinical Safety, Bristol Myers Squibb, Summit, NJ, USA., Papadopoulos G; Drug Safety Research and Evaluation, Takeda Pharmaceuticals, Cambridge, MA, USA., Freag M; Drug Safety Research and Evaluation, Takeda Pharmaceuticals, Cambridge, MA, USA., Chan TS; Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Homan KA; Complex in vitro Systems, Genentech Inc, South San Francisco, CA, USA., Fellows MD; Cell & Gene Therapy Safety, Clinical Pharmacology & Safety Science, R&D, AstraZeneca, Cambridge, UK., Pointon A; Cell & Gene Therapy Safety, Clinical Pharmacology & Safety Science, R&D, AstraZeneca, Cambridge, UK., Kojala K; Nonclinical Safety, Bristol Myers Squibb, Summit, NJ, USA.

Publikováno v: ALTEX [ALTEX] 2024; Vol. 41 (3), pp. 469-484. Date of Electronic Publication: 2024 May 15.